What do you do when bored on a slow rainy night,
when the frenzied funding conspirators on HC, are huddling together in the corner of another thread,
muttering dark thoughts and whispering fears about CRs, CRs, CRs …
and you start wondering if their autophagy systems are working efficiently…
" ... stop, we don’t wish that on anybody …."
Well, of course, you go read up on recent biopharma takeovers, start feeling happy, and start dreaming big…
And I’ve read some good deep dive articles from this outlet…they seem to have some decent cred…
https://www.biopharmadive.com/
and I was reading this article…
and hada thought …
"I wonder if this media outleteven knowsabout Pharmaust??"
So I did aSearch…
"ok, that’s not good … that needs fixing … but what can I do …?”
“And, is it worth the effort?” "Who is this Company?"
Hmmm … Opened offices in NYC, London and Dhaka, Bangladesh
"Ok, that’s a global audience…"
"Maybe, but how ..." and ... "I wonder - who are the Editors?" "Where's the contact point?"
https://www.biopharmadive.com/submit-tip/
"Perfect."
“Be positive” “Be pro-active” “If you don’t try, you don’t get” “You’ll never, never know……."
"Just do it..."
—— —— —— —— —— —— —— —— —— —— —— —— —— —— —— —— ——
Title:
Hope for MND/ALS - Breakthrough data shows significant reduction in risk of death by 91 %
Breakthrough in hope for MND/ALS
5 June 2024
Headline news: Treatment with monepantel significantly reduces the risk of death by 91%
(HR=0.087, p=0.0154) compared to PRO-ACT matched controls.
About PharmAust Limited:PharmAust Limited is listed on the Australian Securities Exchange (ASX Code: PAA). PAA is a clinical-stage biotechnology company developing therapeutics for neurodegenerative diseases. The company is focused on repurposing monepantel (MPL) for amyotrophic lateral sclerosis (ALS). ALSis the most common form of motor neurone disease (MND) and affects both upper and lower motor neurons.
MPL is a potent and safe inhibitor of the mTOR pathway. This pathway plays a central role in the growth and proliferation of cancer cells and degenerating neurons. The mTOR pathway regulates the cellular “cleaning process”, where toxic proteins are broken down into macromolecules to be reused.
This autophagic process is disrupted in most neurodegenerative diseases, including ALS.
The company recently announced positive top-line results for its Phase 1 MEND study in patients with ALS.
PAA is in the planning stages for a registration adaptive Phase 2/3 STRIKE clinical study and anticipates commencing enrolment in H2 CY 2024. This single pivotal study could potentially lead to accelerated approval with the US Food and Drug Administration for monepantel for the treatment of ALS in 2026.
This looks to be the next big story in the treatment for MND/ALS particularly with the recent demise of standard of care drugs on the market. Thanks for your time.
—— —— —— —— —— —— —— —— —— —— —— —— —— —— —— —— ——
start dreaming big again …
that receptionist, or PA trying to impress the boss, says to the CEO, “Did you see this article?” ...
and …
and then …
PAA get an email …. 
Ok, stop, back to the takeover dream …
TEASER ALERT !!
So, I found this databasereport of drugmaker buyouts in 2024 …
"eyes wide open"
hmmm,that really belongs in the pipeline thread …..
fine. switching gears ….
cheers,
Ice
maybe a glass of wine first... 
(20min delay)